Unfortunately, recentstudies reveal the tumor-promoting and pro-angiogenic PPARγ activities; while in most cases PPARγ agonists attenuate tumor growth and angiogenesis,troglitazone (TGZ, a now rejected PPARγ agonist) promotes hepaticcarcinogenesis and liposarcomas. The gene discussed is PPARG; the disease is liposarcoma.